nodes	percent_of_prediction	percent_of_DWPC	metapath
Amprenavir—ABCC1—Mitoxantrone—multiple sclerosis	0.135	0.171	CbGbCtD
Amprenavir—CYP2D6—Fingolimod—multiple sclerosis	0.0655	0.0827	CbGbCtD
Amprenavir—ABCC1—Methotrexate—multiple sclerosis	0.0564	0.0712	CbGbCtD
Amprenavir—ABCB1—Methylprednisolone—multiple sclerosis	0.0448	0.0566	CbGbCtD
Amprenavir—CYP3A4—Fingolimod—multiple sclerosis	0.0416	0.0526	CbGbCtD
Amprenavir—CYP2C19—Prednisone—multiple sclerosis	0.0336	0.0425	CbGbCtD
Amprenavir—CYP2B6—Dexamethasone—multiple sclerosis	0.033	0.0417	CbGbCtD
Amprenavir—ABCB1—Mitoxantrone—multiple sclerosis	0.0327	0.0413	CbGbCtD
Amprenavir—ABCB1—Betamethasone—multiple sclerosis	0.0291	0.0368	CbGbCtD
Amprenavir—ABCB1—Prednisolone—multiple sclerosis	0.0287	0.0363	CbGbCtD
Amprenavir—ABCB1—Prednisone—multiple sclerosis	0.0271	0.0343	CbGbCtD
Amprenavir—CYP3A4—Methylprednisolone—multiple sclerosis	0.0268	0.0339	CbGbCtD
Amprenavir—CYP3A5—Dexamethasone—multiple sclerosis	0.026	0.0329	CbGbCtD
Amprenavir—CYP2C8—Dexamethasone—multiple sclerosis	0.025	0.0316	CbGbCtD
Amprenavir—CYP2C19—Dexamethasone—multiple sclerosis	0.021	0.0265	CbGbCtD
Amprenavir—CYP3A4—Triamcinolone—multiple sclerosis	0.0203	0.0257	CbGbCtD
Amprenavir—CYP3A4—Mitoxantrone—multiple sclerosis	0.0196	0.0247	CbGbCtD
Amprenavir—CYP2C9—Dexamethasone—multiple sclerosis	0.0175	0.022	CbGbCtD
Amprenavir—CYP3A4—Betamethasone—multiple sclerosis	0.0174	0.022	CbGbCtD
Amprenavir—CYP3A4—Prednisolone—multiple sclerosis	0.0172	0.0217	CbGbCtD
Amprenavir—ABCB1—Dexamethasone—multiple sclerosis	0.0169	0.0214	CbGbCtD
Amprenavir—CYP3A4—Prednisone—multiple sclerosis	0.0163	0.0205	CbGbCtD
Amprenavir—CYP2D6—Dexamethasone—multiple sclerosis	0.016	0.0202	CbGbCtD
Amprenavir—ABCB1—Methotrexate—multiple sclerosis	0.0136	0.0172	CbGbCtD
Amprenavir—CYP3A4—Dexamethasone—multiple sclerosis	0.0101	0.0128	CbGbCtD
Amprenavir—Nervous system disorder—Fingolimod—multiple sclerosis	0.00117	0.00673	CcSEcCtD
Amprenavir—Skin disorder—Fingolimod—multiple sclerosis	0.00116	0.00667	CcSEcCtD
Amprenavir—Abdominal discomfort—Cladribine—multiple sclerosis	0.00114	0.00656	CcSEcCtD
Amprenavir—Blood triglycerides increased—Prednisone—multiple sclerosis	0.00114	0.00652	CcSEcCtD
Amprenavir—Neutropenia—Cladribine—multiple sclerosis	0.00111	0.0064	CcSEcCtD
Amprenavir—Paraesthesia—Fingolimod—multiple sclerosis	0.00107	0.00617	CcSEcCtD
Amprenavir—Stevens-Johnson syndrome—Cladribine—multiple sclerosis	0.00105	0.00605	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.00103	0.00593	CcSEcCtD
Amprenavir—Fatigue—Fingolimod—multiple sclerosis	0.00103	0.00592	CcSEcCtD
Amprenavir—Hepatobiliary disease—Cladribine—multiple sclerosis	0.001	0.00577	CcSEcCtD
Amprenavir—Inflammation—Methylprednisolone—multiple sclerosis	0.000969	0.00556	CcSEcCtD
Amprenavir—Connective tissue disorder—Cladribine—multiple sclerosis	0.000937	0.00538	CcSEcCtD
Amprenavir—Abdominal discomfort—Azathioprine—multiple sclerosis	0.000929	0.00534	CcSEcCtD
Amprenavir—Erythema multiforme—Cladribine—multiple sclerosis	0.000902	0.00518	CcSEcCtD
Amprenavir—Cardiac disorder—Cladribine—multiple sclerosis	0.000885	0.00508	CcSEcCtD
Amprenavir—Asthenia—Fingolimod—multiple sclerosis	0.000858	0.00493	CcSEcCtD
Amprenavir—Stevens-Johnson syndrome—Azathioprine—multiple sclerosis	0.000856	0.00492	CcSEcCtD
Amprenavir—Diabetes mellitus—Prednisolone—multiple sclerosis	0.000855	0.00491	CcSEcCtD
Amprenavir—Pruritus—Fingolimod—multiple sclerosis	0.000846	0.00486	CcSEcCtD
Amprenavir—Mental disorder—Cladribine—multiple sclerosis	0.000836	0.0048	CcSEcCtD
Amprenavir—Malnutrition—Cladribine—multiple sclerosis	0.00083	0.00477	CcSEcCtD
Amprenavir—Flatulence—Cladribine—multiple sclerosis	0.000818	0.0047	CcSEcCtD
Amprenavir—Diarrhoea—Fingolimod—multiple sclerosis	0.000818	0.0047	CcSEcCtD
Amprenavir—Hepatobiliary disease—Azathioprine—multiple sclerosis	0.000817	0.00469	CcSEcCtD
Amprenavir—Aspartate aminotransferase increased—Mitoxantrone—multiple sclerosis	0.000816	0.00469	CcSEcCtD
Amprenavir—Alanine aminotransferase increased—Mitoxantrone—multiple sclerosis	0.000799	0.00459	CcSEcCtD
Amprenavir—Hypercholesterolaemia—Prednisone—multiple sclerosis	0.000787	0.00452	CcSEcCtD
Amprenavir—Diabetes mellitus—Triamcinolone—multiple sclerosis	0.000786	0.00451	CcSEcCtD
Amprenavir—Diabetes mellitus—Methylprednisolone—multiple sclerosis	0.000784	0.0045	CcSEcCtD
Amprenavir—Headache—Fingolimod—multiple sclerosis	0.000749	0.0043	CcSEcCtD
Amprenavir—Erythema multiforme—Azathioprine—multiple sclerosis	0.000733	0.00421	CcSEcCtD
Amprenavir—Neutropenia—Mitoxantrone—multiple sclerosis	0.000732	0.00421	CcSEcCtD
Amprenavir—Diabetes mellitus—Dexamethasone—multiple sclerosis	0.000713	0.0041	CcSEcCtD
Amprenavir—Diabetes mellitus—Betamethasone—multiple sclerosis	0.000713	0.0041	CcSEcCtD
Amprenavir—Myalgia—Cladribine—multiple sclerosis	0.000707	0.00406	CcSEcCtD
Amprenavir—Hyperglycaemia—Mitoxantrone—multiple sclerosis	0.000707	0.00406	CcSEcCtD
Amprenavir—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.000702	0.00403	CcSEcCtD
Amprenavir—Discomfort—Cladribine—multiple sclerosis	0.000698	0.00401	CcSEcCtD
Amprenavir—Acute coronary syndrome—Mitoxantrone—multiple sclerosis	0.000688	0.00395	CcSEcCtD
Amprenavir—Myocardial infarction—Mitoxantrone—multiple sclerosis	0.000685	0.00393	CcSEcCtD
Amprenavir—Hyperbilirubinaemia—Methotrexate—multiple sclerosis	0.000684	0.00393	CcSEcCtD
Amprenavir—Nervous system disorder—Cladribine—multiple sclerosis	0.000665	0.00382	CcSEcCtD
Amprenavir—Skin disorder—Cladribine—multiple sclerosis	0.000658	0.00378	CcSEcCtD
Amprenavir—Anorexia—Cladribine—multiple sclerosis	0.000646	0.00371	CcSEcCtD
Amprenavir—Inflammation—Methotrexate—multiple sclerosis	0.000641	0.00368	CcSEcCtD
Amprenavir—Diabetes mellitus—Prednisone—multiple sclerosis	0.000621	0.00357	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Cladribine—multiple sclerosis	0.000617	0.00355	CcSEcCtD
Amprenavir—Paraesthesia—Cladribine—multiple sclerosis	0.000608	0.00349	CcSEcCtD
Amprenavir—Alanine aminotransferase increased—Methylprednisolone—multiple sclerosis	0.000602	0.00346	CcSEcCtD
Amprenavir—Decreased appetite—Cladribine—multiple sclerosis	0.000589	0.00338	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000585	0.00336	CcSEcCtD
Amprenavir—Fatigue—Cladribine—multiple sclerosis	0.000584	0.00336	CcSEcCtD
Amprenavir—Myalgia—Azathioprine—multiple sclerosis	0.000575	0.0033	CcSEcCtD
Amprenavir—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000571	0.00328	CcSEcCtD
Amprenavir—Discomfort—Azathioprine—multiple sclerosis	0.000568	0.00326	CcSEcCtD
Amprenavir—Acute coronary syndrome—Prednisolone—multiple sclerosis	0.000565	0.00324	CcSEcCtD
Amprenavir—Myocardial infarction—Prednisolone—multiple sclerosis	0.000562	0.00323	CcSEcCtD
Amprenavir—Gastrointestinal pain—Cladribine—multiple sclerosis	0.000554	0.00318	CcSEcCtD
Amprenavir—Abdominal pain—Cladribine—multiple sclerosis	0.000536	0.00308	CcSEcCtD
Amprenavir—Skin disorder—Azathioprine—multiple sclerosis	0.000535	0.00307	CcSEcCtD
Amprenavir—Acute coronary syndrome—Triamcinolone—multiple sclerosis	0.000519	0.00298	CcSEcCtD
Amprenavir—Diabetes mellitus—Methotrexate—multiple sclerosis	0.000519	0.00298	CcSEcCtD
Amprenavir—Acute coronary syndrome—Methylprednisolone—multiple sclerosis	0.000518	0.00298	CcSEcCtD
Amprenavir—Myocardial infarction—Triamcinolone—multiple sclerosis	0.000516	0.00297	CcSEcCtD
Amprenavir—Myocardial infarction—Methylprednisolone—multiple sclerosis	0.000515	0.00296	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Azathioprine—multiple sclerosis	0.000502	0.00288	CcSEcCtD
Amprenavir—Asthenia—Cladribine—multiple sclerosis	0.000486	0.00279	CcSEcCtD
Amprenavir—Hyperglycaemia—Betamethasone—multiple sclerosis	0.000484	0.00278	CcSEcCtD
Amprenavir—Hyperglycaemia—Dexamethasone—multiple sclerosis	0.000484	0.00278	CcSEcCtD
Amprenavir—Pruritus—Cladribine—multiple sclerosis	0.000479	0.00275	CcSEcCtD
Amprenavir—Alanine aminotransferase increased—Prednisone—multiple sclerosis	0.000476	0.00274	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000476	0.00273	CcSEcCtD
Amprenavir—Acute coronary syndrome—Dexamethasone—multiple sclerosis	0.000471	0.00271	CcSEcCtD
Amprenavir—Acute coronary syndrome—Betamethasone—multiple sclerosis	0.000471	0.00271	CcSEcCtD
Amprenavir—Myocardial infarction—Dexamethasone—multiple sclerosis	0.000469	0.00269	CcSEcCtD
Amprenavir—Myocardial infarction—Betamethasone—multiple sclerosis	0.000469	0.00269	CcSEcCtD
Amprenavir—Myalgia—Mitoxantrone—multiple sclerosis	0.000465	0.00267	CcSEcCtD
Amprenavir—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.000464	0.00266	CcSEcCtD
Amprenavir—Diarrhoea—Cladribine—multiple sclerosis	0.000464	0.00266	CcSEcCtD
Amprenavir—Discomfort—Mitoxantrone—multiple sclerosis	0.000459	0.00264	CcSEcCtD
Amprenavir—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000451	0.00259	CcSEcCtD
Amprenavir—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000438	0.00252	CcSEcCtD
Amprenavir—Neutropenia—Prednisone—multiple sclerosis	0.000437	0.00251	CcSEcCtD
Amprenavir—Abdominal pain—Azathioprine—multiple sclerosis	0.000436	0.0025	CcSEcCtD
Amprenavir—Skin disorder—Mitoxantrone—multiple sclerosis	0.000433	0.00248	CcSEcCtD
Amprenavir—Vomiting—Cladribine—multiple sclerosis	0.000431	0.00247	CcSEcCtD
Amprenavir—Rash—Cladribine—multiple sclerosis	0.000427	0.00245	CcSEcCtD
Amprenavir—Dermatitis—Cladribine—multiple sclerosis	0.000427	0.00245	CcSEcCtD
Amprenavir—Anorexia—Mitoxantrone—multiple sclerosis	0.000425	0.00244	CcSEcCtD
Amprenavir—Headache—Cladribine—multiple sclerosis	0.000425	0.00244	CcSEcCtD
Amprenavir—Hyperglycaemia—Prednisone—multiple sclerosis	0.000421	0.00242	CcSEcCtD
Amprenavir—Liver function test abnormal—Methotrexate—multiple sclerosis	0.000417	0.00239	CcSEcCtD
Amprenavir—Depression—Prednisone—multiple sclerosis	0.000415	0.00238	CcSEcCtD
Amprenavir—Mental disorder—Methylprednisolone—multiple sclerosis	0.000413	0.00237	CcSEcCtD
Amprenavir—Malnutrition—Methylprednisolone—multiple sclerosis	0.000411	0.00236	CcSEcCtD
Amprenavir—Acute coronary syndrome—Prednisone—multiple sclerosis	0.00041	0.00236	CcSEcCtD
Amprenavir—Angioedema—Prednisolone—multiple sclerosis	0.000409	0.00235	CcSEcCtD
Amprenavir—Myocardial infarction—Prednisone—multiple sclerosis	0.000408	0.00234	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000406	0.00233	CcSEcCtD
Amprenavir—Nausea—Cladribine—multiple sclerosis	0.000402	0.00231	CcSEcCtD
Amprenavir—Paraesthesia—Mitoxantrone—multiple sclerosis	0.0004	0.0023	CcSEcCtD
Amprenavir—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000387	0.00222	CcSEcCtD
Amprenavir—Fatigue—Mitoxantrone—multiple sclerosis	0.000384	0.00221	CcSEcCtD
Amprenavir—Diarrhoea—Azathioprine—multiple sclerosis	0.000377	0.00217	CcSEcCtD
Amprenavir—Discomfort—Prednisolone—multiple sclerosis	0.000377	0.00216	CcSEcCtD
Amprenavir—Angioedema—Triamcinolone—multiple sclerosis	0.000376	0.00216	CcSEcCtD
Amprenavir—Angioedema—Methylprednisolone—multiple sclerosis	0.000375	0.00216	CcSEcCtD
Amprenavir—Abdominal discomfort—Methotrexate—multiple sclerosis	0.000374	0.00215	CcSEcCtD
Amprenavir—Connective tissue disorder—Prednisone—multiple sclerosis	0.000367	0.00211	CcSEcCtD
Amprenavir—Neutropenia—Methotrexate—multiple sclerosis	0.000365	0.0021	CcSEcCtD
Amprenavir—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000364	0.00209	CcSEcCtD
Amprenavir—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000352	0.00202	CcSEcCtD
Amprenavir—Myalgia—Triamcinolone—multiple sclerosis	0.000351	0.00201	CcSEcCtD
Amprenavir—Vomiting—Azathioprine—multiple sclerosis	0.00035	0.00201	CcSEcCtD
Amprenavir—Myalgia—Methylprednisolone—multiple sclerosis	0.00035	0.00201	CcSEcCtD
Amprenavir—Rash—Azathioprine—multiple sclerosis	0.000347	0.002	CcSEcCtD
Amprenavir—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000347	0.002	CcSEcCtD
Amprenavir—Dermatitis—Azathioprine—multiple sclerosis	0.000347	0.00199	CcSEcCtD
Amprenavir—Depression—Methotrexate—multiple sclerosis	0.000347	0.00199	CcSEcCtD
Amprenavir—Discomfort—Triamcinolone—multiple sclerosis	0.000346	0.00199	CcSEcCtD
Amprenavir—Discomfort—Methylprednisolone—multiple sclerosis	0.000346	0.00198	CcSEcCtD
Amprenavir—Headache—Azathioprine—multiple sclerosis	0.000345	0.00198	CcSEcCtD
Amprenavir—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000345	0.00198	CcSEcCtD
Amprenavir—Angioedema—Dexamethasone—multiple sclerosis	0.000341	0.00196	CcSEcCtD
Amprenavir—Angioedema—Betamethasone—multiple sclerosis	0.000341	0.00196	CcSEcCtD
Amprenavir—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000329	0.00189	CcSEcCtD
Amprenavir—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000329	0.00189	CcSEcCtD
Amprenavir—Paraesthesia—Prednisolone—multiple sclerosis	0.000328	0.00188	CcSEcCtD
Amprenavir—Mental disorder—Prednisone—multiple sclerosis	0.000327	0.00188	CcSEcCtD
Amprenavir—Nausea—Azathioprine—multiple sclerosis	0.000327	0.00188	CcSEcCtD
Amprenavir—Skin disorder—Methylprednisolone—multiple sclerosis	0.000326	0.00187	CcSEcCtD
Amprenavir—Malnutrition—Prednisone—multiple sclerosis	0.000325	0.00187	CcSEcCtD
Amprenavir—Asthenia—Mitoxantrone—multiple sclerosis	0.00032	0.00184	CcSEcCtD
Amprenavir—Myalgia—Betamethasone—multiple sclerosis	0.000318	0.00183	CcSEcCtD
Amprenavir—Myalgia—Dexamethasone—multiple sclerosis	0.000318	0.00183	CcSEcCtD
Amprenavir—Discomfort—Betamethasone—multiple sclerosis	0.000314	0.0018	CcSEcCtD
Amprenavir—Discomfort—Dexamethasone—multiple sclerosis	0.000314	0.0018	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000306	0.00176	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000305	0.00175	CcSEcCtD
Amprenavir—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000305	0.00175	CcSEcCtD
Amprenavir—Paraesthesia—Triamcinolone—multiple sclerosis	0.000302	0.00173	CcSEcCtD
Amprenavir—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000301	0.00173	CcSEcCtD
Amprenavir—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000299	0.00172	CcSEcCtD
Amprenavir—Nervous system disorder—Betamethasone—multiple sclerosis	0.000299	0.00172	CcSEcCtD
Amprenavir—Angioedema—Prednisone—multiple sclerosis	0.000297	0.00171	CcSEcCtD
Amprenavir—Erythema multiforme—Methotrexate—multiple sclerosis	0.000295	0.0017	CcSEcCtD
Amprenavir—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000292	0.00858	CbGpPWpGaD
Amprenavir—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000292	0.00858	CbGpPWpGaD
Amprenavir—Anorexia—Betamethasone—multiple sclerosis	0.000291	0.00167	CcSEcCtD
Amprenavir—Anorexia—Dexamethasone—multiple sclerosis	0.000291	0.00167	CcSEcCtD
Amprenavir—Cardiac disorder—Methotrexate—multiple sclerosis	0.00029	0.00167	CcSEcCtD
Amprenavir—Fatigue—Triamcinolone—multiple sclerosis	0.00029	0.00166	CcSEcCtD
Amprenavir—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000289	0.00851	CbGpPWpGaD
Amprenavir—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000289	0.00851	CbGpPWpGaD
Amprenavir—Fatigue—Methylprednisolone—multiple sclerosis	0.000289	0.00166	CcSEcCtD
Amprenavir—CYP2C8—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000288	0.00847	CbGpPWpGaD
Amprenavir—CYP2C8—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000288	0.00847	CbGpPWpGaD
Amprenavir—CYP2D6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000288	0.00847	CbGpPWpGaD
Amprenavir—CYP2D6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000288	0.00847	CbGpPWpGaD
Amprenavir—CYP2C9—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000286	0.00839	CbGpPWpGaD
Amprenavir—CYP2C9—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000286	0.00839	CbGpPWpGaD
Amprenavir—Vomiting—Mitoxantrone—multiple sclerosis	0.000283	0.00163	CcSEcCtD
Amprenavir—Rash—Mitoxantrone—multiple sclerosis	0.000281	0.00161	CcSEcCtD
Amprenavir—Dermatitis—Mitoxantrone—multiple sclerosis	0.000281	0.00161	CcSEcCtD
Amprenavir—Headache—Mitoxantrone—multiple sclerosis	0.000279	0.0016	CcSEcCtD
Amprenavir—ABCB1—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000278	0.00817	CbGpPWpGaD
Amprenavir—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000278	0.0016	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000278	0.0016	CcSEcCtD
Amprenavir—Myalgia—Prednisone—multiple sclerosis	0.000277	0.00159	CcSEcCtD
Amprenavir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000275	0.00158	CcSEcCtD
Amprenavir—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000274	0.00157	CcSEcCtD
Amprenavir—Paraesthesia—Dexamethasone—multiple sclerosis	0.000274	0.00157	CcSEcCtD
Amprenavir—Paraesthesia—Betamethasone—multiple sclerosis	0.000274	0.00157	CcSEcCtD
Amprenavir—Discomfort—Prednisone—multiple sclerosis	0.000274	0.00157	CcSEcCtD
Amprenavir—Mental disorder—Methotrexate—multiple sclerosis	0.000274	0.00157	CcSEcCtD
Amprenavir—Malnutrition—Methotrexate—multiple sclerosis	0.000272	0.00156	CcSEcCtD
Amprenavir—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000266	0.00782	CbGpPWpGaD
Amprenavir—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000265	0.00152	CcSEcCtD
Amprenavir—Decreased appetite—Dexamethasone—multiple sclerosis	0.000265	0.00152	CcSEcCtD
Amprenavir—Decreased appetite—Betamethasone—multiple sclerosis	0.000265	0.00152	CcSEcCtD
Amprenavir—Nausea—Mitoxantrone—multiple sclerosis	0.000265	0.00152	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000263	0.00151	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000263	0.00151	CcSEcCtD
Amprenavir—Fatigue—Betamethasone—multiple sclerosis	0.000263	0.00151	CcSEcCtD
Amprenavir—Fatigue—Dexamethasone—multiple sclerosis	0.000263	0.00151	CcSEcCtD
Amprenavir—Nervous system disorder—Prednisone—multiple sclerosis	0.00026	0.0015	CcSEcCtD
Amprenavir—Skin disorder—Prednisone—multiple sclerosis	0.000258	0.00148	CcSEcCtD
Amprenavir—CYP2C19—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000257	0.00756	CbGpPWpGaD
Amprenavir—CYP2C19—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000257	0.00756	CbGpPWpGaD
Amprenavir—Anorexia—Prednisone—multiple sclerosis	0.000253	0.00145	CcSEcCtD
Amprenavir—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000249	0.00143	CcSEcCtD
Amprenavir—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000249	0.00143	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000242	0.00139	CcSEcCtD
Amprenavir—Asthenia—Triamcinolone—multiple sclerosis	0.000241	0.00138	CcSEcCtD
Amprenavir—Abdominal pain—Dexamethasone—multiple sclerosis	0.000241	0.00138	CcSEcCtD
Amprenavir—Abdominal pain—Betamethasone—multiple sclerosis	0.000241	0.00138	CcSEcCtD
Amprenavir—Asthenia—Methylprednisolone—multiple sclerosis	0.000241	0.00138	CcSEcCtD
Amprenavir—Paraesthesia—Prednisone—multiple sclerosis	0.000238	0.00137	CcSEcCtD
Amprenavir—Pruritus—Triamcinolone—multiple sclerosis	0.000238	0.00137	CcSEcCtD
Amprenavir—Pruritus—Methylprednisolone—multiple sclerosis	0.000237	0.00136	CcSEcCtD
Amprenavir—CYP2D6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000237	0.00696	CbGpPWpGaD
Amprenavir—CYP2D6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000237	0.00696	CbGpPWpGaD
Amprenavir—CYP2C9—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000235	0.0069	CbGpPWpGaD
Amprenavir—CYP2C9—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000235	0.0069	CbGpPWpGaD
Amprenavir—Myalgia—Methotrexate—multiple sclerosis	0.000231	0.00133	CcSEcCtD
Amprenavir—Decreased appetite—Prednisone—multiple sclerosis	0.000231	0.00133	CcSEcCtD
Amprenavir—Rash—Prednisolone—multiple sclerosis	0.00023	0.00132	CcSEcCtD
Amprenavir—Dermatitis—Prednisolone—multiple sclerosis	0.00023	0.00132	CcSEcCtD
Amprenavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.00023	0.00132	CcSEcCtD
Amprenavir—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000229	0.00132	CcSEcCtD
Amprenavir—Fatigue—Prednisone—multiple sclerosis	0.000229	0.00131	CcSEcCtD
Amprenavir—Headache—Prednisolone—multiple sclerosis	0.000229	0.00131	CcSEcCtD
Amprenavir—Discomfort—Methotrexate—multiple sclerosis	0.000229	0.00131	CcSEcCtD
Amprenavir—Asthenia—Dexamethasone—multiple sclerosis	0.000219	0.00126	CcSEcCtD
Amprenavir—Asthenia—Betamethasone—multiple sclerosis	0.000219	0.00126	CcSEcCtD
Amprenavir—Nervous system disorder—Methotrexate—multiple sclerosis	0.000218	0.00125	CcSEcCtD
Amprenavir—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000217	0.00125	CcSEcCtD
Amprenavir—Nausea—Prednisolone—multiple sclerosis	0.000217	0.00125	CcSEcCtD
Amprenavir—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000217	0.00636	CbGpPWpGaD
Amprenavir—Pruritus—Betamethasone—multiple sclerosis	0.000216	0.00124	CcSEcCtD
Amprenavir—Pruritus—Dexamethasone—multiple sclerosis	0.000216	0.00124	CcSEcCtD
Amprenavir—Skin disorder—Methotrexate—multiple sclerosis	0.000216	0.00124	CcSEcCtD
Amprenavir—Vomiting—Triamcinolone—multiple sclerosis	0.000214	0.00123	CcSEcCtD
Amprenavir—Vomiting—Methylprednisolone—multiple sclerosis	0.000213	0.00122	CcSEcCtD
Amprenavir—Rash—Triamcinolone—multiple sclerosis	0.000212	0.00122	CcSEcCtD
Amprenavir—Dermatitis—Triamcinolone—multiple sclerosis	0.000212	0.00122	CcSEcCtD
Amprenavir—Anorexia—Methotrexate—multiple sclerosis	0.000212	0.00121	CcSEcCtD
Amprenavir—ABCB1—Allograft Rejection—C4A—multiple sclerosis	0.000211	0.00621	CbGpPWpGaD
Amprenavir—Rash—Methylprednisolone—multiple sclerosis	0.000211	0.00121	CcSEcCtD
Amprenavir—Dermatitis—Methylprednisolone—multiple sclerosis	0.000211	0.00121	CcSEcCtD
Amprenavir—Headache—Triamcinolone—multiple sclerosis	0.000211	0.00121	CcSEcCtD
Amprenavir—Headache—Methylprednisolone—multiple sclerosis	0.00021	0.00121	CcSEcCtD
Amprenavir—Abdominal pain—Prednisone—multiple sclerosis	0.00021	0.00121	CcSEcCtD
Amprenavir—Diarrhoea—Dexamethasone—multiple sclerosis	0.000209	0.0012	CcSEcCtD
Amprenavir—Diarrhoea—Betamethasone—multiple sclerosis	0.000209	0.0012	CcSEcCtD
Amprenavir—ABCC1—S1P1 pathway—MAPK1—multiple sclerosis	0.000208	0.00611	CbGpPWpGaD
Amprenavir—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000202	0.00116	CcSEcCtD
Amprenavir—Nausea—Triamcinolone—multiple sclerosis	0.0002	0.00115	CcSEcCtD
Amprenavir—Paraesthesia—Methotrexate—multiple sclerosis	0.000199	0.00114	CcSEcCtD
Amprenavir—Nausea—Methylprednisolone—multiple sclerosis	0.000199	0.00114	CcSEcCtD
Amprenavir—Vomiting—Betamethasone—multiple sclerosis	0.000194	0.00111	CcSEcCtD
Amprenavir—Vomiting—Dexamethasone—multiple sclerosis	0.000194	0.00111	CcSEcCtD
Amprenavir—Decreased appetite—Methotrexate—multiple sclerosis	0.000193	0.00111	CcSEcCtD
Amprenavir—Rash—Betamethasone—multiple sclerosis	0.000192	0.0011	CcSEcCtD
Amprenavir—Rash—Dexamethasone—multiple sclerosis	0.000192	0.0011	CcSEcCtD
Amprenavir—Dermatitis—Dexamethasone—multiple sclerosis	0.000192	0.0011	CcSEcCtD
Amprenavir—Dermatitis—Betamethasone—multiple sclerosis	0.000192	0.0011	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000192	0.0011	CcSEcCtD
Amprenavir—Fatigue—Methotrexate—multiple sclerosis	0.000191	0.0011	CcSEcCtD
Amprenavir—Headache—Dexamethasone—multiple sclerosis	0.000191	0.0011	CcSEcCtD
Amprenavir—Headache—Betamethasone—multiple sclerosis	0.000191	0.0011	CcSEcCtD
Amprenavir—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000191	0.00561	CbGpPWpGaD
Amprenavir—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000191	0.00561	CbGpPWpGaD
Amprenavir—Asthenia—Prednisone—multiple sclerosis	0.000191	0.00109	CcSEcCtD
Amprenavir—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000188	0.00554	CbGpPWpGaD
Amprenavir—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000188	0.00554	CbGpPWpGaD
Amprenavir—Pruritus—Prednisone—multiple sclerosis	0.000188	0.00108	CcSEcCtD
Amprenavir—Diarrhoea—Prednisone—multiple sclerosis	0.000182	0.00104	CcSEcCtD
Amprenavir—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000181	0.00104	CcSEcCtD
Amprenavir—Nausea—Betamethasone—multiple sclerosis	0.000181	0.00104	CcSEcCtD
Amprenavir—Nausea—Dexamethasone—multiple sclerosis	0.000181	0.00104	CcSEcCtD
Amprenavir—CYP2B6—Biological oxidations—CYP27B1—multiple sclerosis	0.000181	0.00532	CbGpPWpGaD
Amprenavir—CYP2B6—Biological oxidations—CYP24A1—multiple sclerosis	0.000181	0.00532	CbGpPWpGaD
Amprenavir—CYP2B6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000178	0.00524	CbGpPWpGaD
Amprenavir—CYP2B6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000178	0.00524	CbGpPWpGaD
Amprenavir—CYP3A5—Biological oxidations—CYP24A1—multiple sclerosis	0.000177	0.0052	CbGpPWpGaD
Amprenavir—CYP3A5—Biological oxidations—CYP27B1—multiple sclerosis	0.000177	0.0052	CbGpPWpGaD
Amprenavir—Abdominal pain—Methotrexate—multiple sclerosis	0.000175	0.00101	CcSEcCtD
Amprenavir—CYP3A5—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000174	0.00513	CbGpPWpGaD
Amprenavir—CYP3A5—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000174	0.00513	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—CXCL13—multiple sclerosis	0.000172	0.00506	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—IL12A—multiple sclerosis	0.000172	0.00506	CbGpPWpGaD
Amprenavir—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000171	0.00503	CbGpPWpGaD
Amprenavir—Vomiting—Prednisone—multiple sclerosis	0.000169	0.00097	CcSEcCtD
Amprenavir—Rash—Prednisone—multiple sclerosis	0.000167	0.000962	CcSEcCtD
Amprenavir—Dermatitis—Prednisone—multiple sclerosis	0.000167	0.000961	CcSEcCtD
Amprenavir—Headache—Prednisone—multiple sclerosis	0.000166	0.000955	CcSEcCtD
Amprenavir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.00016	0.00469	CbGpPWpGaD
Amprenavir—Asthenia—Methotrexate—multiple sclerosis	0.000159	0.000915	CcSEcCtD
Amprenavir—Nausea—Prednisone—multiple sclerosis	0.000158	0.000906	CcSEcCtD
Amprenavir—Pruritus—Methotrexate—multiple sclerosis	0.000157	0.000902	CcSEcCtD
Amprenavir—ABCB1—Allograft Rejection—HLA-DRA—multiple sclerosis	0.000157	0.00461	CbGpPWpGaD
Amprenavir—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000155	0.00455	CbGpPWpGaD
Amprenavir—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000155	0.00455	CbGpPWpGaD
Amprenavir—CYP2C8—Biological oxidations—CYP24A1—multiple sclerosis	0.000153	0.0045	CbGpPWpGaD
Amprenavir—CYP2C8—Biological oxidations—CYP27B1—multiple sclerosis	0.000153	0.0045	CbGpPWpGaD
Amprenavir—Diarrhoea—Methotrexate—multiple sclerosis	0.000152	0.000872	CcSEcCtD
Amprenavir—CYP2C8—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000151	0.00444	CbGpPWpGaD
Amprenavir—CYP2C8—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000151	0.00444	CbGpPWpGaD
Amprenavir—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000149	0.00438	CbGpPWpGaD
Amprenavir—CYP2C19—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000149	0.00437	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—FOXP3—multiple sclerosis	0.000148	0.00435	CbGpPWpGaD
Amprenavir—Vomiting—Methotrexate—multiple sclerosis	0.000141	0.00081	CcSEcCtD
Amprenavir—Rash—Methotrexate—multiple sclerosis	0.00014	0.000804	CcSEcCtD
Amprenavir—Dermatitis—Methotrexate—multiple sclerosis	0.00014	0.000803	CcSEcCtD
Amprenavir—Headache—Methotrexate—multiple sclerosis	0.000139	0.000799	CcSEcCtD
Amprenavir—CYP2D6—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000137	0.00402	CbGpPWpGaD
Amprenavir—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	0.000137	0.00402	CbGpPWpGaD
Amprenavir—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	0.000137	0.00402	CbGpPWpGaD
Amprenavir—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000135	0.00396	CbGpPWpGaD
Amprenavir—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000135	0.00396	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—HLA-G—multiple sclerosis	0.000134	0.00395	CbGpPWpGaD
Amprenavir—Nausea—Methotrexate—multiple sclerosis	0.000132	0.000757	CcSEcCtD
Amprenavir—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	0.000126	0.0037	CbGpPWpGaD
Amprenavir—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	0.000126	0.0037	CbGpPWpGaD
Amprenavir—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000125	0.00366	CbGpPWpGaD
Amprenavir—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000125	0.00366	CbGpPWpGaD
Amprenavir—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000124	0.00364	CbGpPWpGaD
Amprenavir—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000124	0.00364	CbGpPWpGaD
Amprenavir—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000123	0.00361	CbGpPWpGaD
Amprenavir—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000123	0.00361	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—IL17A—multiple sclerosis	0.000116	0.00342	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—CD28—multiple sclerosis	0.000113	0.00332	CbGpPWpGaD
Amprenavir—ABCC1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.00011	0.00324	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	0.000108	0.00318	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000108	0.00317	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000108	0.00317	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	0.000107	0.00315	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—CD40—multiple sclerosis	0.000103	0.00303	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	0.000102	0.00299	CbGpPWpGaD
Amprenavir—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	9.84e-05	0.00289	CbGpPWpGaD
Amprenavir—CYP2B6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	9.45e-05	0.00278	CbGpPWpGaD
Amprenavir—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	9.3e-05	0.00273	CbGpPWpGaD
Amprenavir—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	9.24e-05	0.00271	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	8.96e-05	0.00263	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	8.38e-05	0.00246	CbGpPWpGaD
Amprenavir—ABCC1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	8.35e-05	0.00245	CbGpPWpGaD
Amprenavir—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	8.22e-05	0.00242	CbGpPWpGaD
Amprenavir—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	8.22e-05	0.00242	CbGpPWpGaD
Amprenavir—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	8.11e-05	0.00238	CbGpPWpGaD
Amprenavir—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	8.11e-05	0.00238	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—CD86—multiple sclerosis	8.07e-05	0.00237	CbGpPWpGaD
Amprenavir—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8e-05	0.00235	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—IL10—multiple sclerosis	7.91e-05	0.00233	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	7.91e-05	0.00233	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—IL4—multiple sclerosis	7.7e-05	0.00226	CbGpPWpGaD
Amprenavir—CYP2B6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.66e-05	0.00225	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	7.53e-05	0.00221	CbGpPWpGaD
Amprenavir—CYP3A5—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.49e-05	0.0022	CbGpPWpGaD
Amprenavir—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.14e-05	0.0021	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—FAS—multiple sclerosis	7.09e-05	0.00208	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	7.05e-05	0.00207	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	6.97e-05	0.00205	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—SRM—multiple sclerosis	6.81e-05	0.002	CbGpPWpGaD
Amprenavir—ABCC1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	6.6e-05	0.00194	CbGpPWpGaD
Amprenavir—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.57e-05	0.00193	CbGpPWpGaD
Amprenavir—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.51e-05	0.00191	CbGpPWpGaD
Amprenavir—CYP2C8—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.49e-05	0.00191	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	6.37e-05	0.00187	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—CD80—multiple sclerosis	5.89e-05	0.00173	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.88e-05	0.00173	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.88e-05	0.00173	CbGpPWpGaD
Amprenavir—ABCC1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	5.83e-05	0.00171	CbGpPWpGaD
Amprenavir—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.79e-05	0.0017	CbGpPWpGaD
Amprenavir—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.33e-05	0.00156	CbGpPWpGaD
Amprenavir—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.28e-05	0.00155	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.25e-05	0.00154	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.25e-05	0.00154	CbGpPWpGaD
Amprenavir—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	5.24e-05	0.00154	CbGpPWpGaD
Amprenavir—ABCC1—Disease—GPC5—multiple sclerosis	5.24e-05	0.00154	CbGpPWpGaD
Amprenavir—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	5.1e-05	0.0015	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—CYP27B1—multiple sclerosis	4.8e-05	0.00141	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—CYP24A1—multiple sclerosis	4.8e-05	0.00141	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	4.79e-05	0.00141	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	4.79e-05	0.00141	CbGpPWpGaD
Amprenavir—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	4.74e-05	0.00139	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	4.69e-05	0.00138	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	4.65e-05	0.00137	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—SRM—multiple sclerosis	4.39e-05	0.00129	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—GPC5—multiple sclerosis	4.39e-05	0.00129	CbGpPWpGaD
Amprenavir—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.29e-05	0.00126	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—SRM—multiple sclerosis	4.29e-05	0.00126	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	4.15e-05	0.00122	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—IL2—multiple sclerosis	4.14e-05	0.00122	CbGpPWpGaD
Amprenavir—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	4.09e-05	0.0012	CbGpPWpGaD
Amprenavir—CYP2B6—Biological oxidations—POMC—multiple sclerosis	4.07e-05	0.0012	CbGpPWpGaD
Amprenavir—CYP3A5—Biological oxidations—POMC—multiple sclerosis	3.98e-05	0.00117	CbGpPWpGaD
Amprenavir—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	3.97e-05	0.00117	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—SRM—multiple sclerosis	3.72e-05	0.00109	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—RRM1—multiple sclerosis	3.64e-05	0.00107	CbGpPWpGaD
Amprenavir—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	3.5e-05	0.00103	CbGpPWpGaD
Amprenavir—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.48e-05	0.00102	CbGpPWpGaD
Amprenavir—CYP2C8—Biological oxidations—POMC—multiple sclerosis	3.45e-05	0.00101	CbGpPWpGaD
Amprenavir—ABCC1—Disease—RPL5—multiple sclerosis	3.41e-05	0.001	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—SRM—multiple sclerosis	3.32e-05	0.000975	CbGpPWpGaD
Amprenavir—ABCC1—Disease—SLC11A1—multiple sclerosis	3.26e-05	0.000959	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—SRM—multiple sclerosis	3.24e-05	0.000952	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	3.23e-05	0.000948	CbGpPWpGaD
Amprenavir—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	3.14e-05	0.000923	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—CYP27B1—multiple sclerosis	3.09e-05	0.000909	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—CYP24A1—multiple sclerosis	3.09e-05	0.000909	CbGpPWpGaD
Amprenavir—CYP2C19—Biological oxidations—POMC—multiple sclerosis	3.08e-05	0.000904	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—SRM—multiple sclerosis	3.05e-05	0.000897	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—SRM—multiple sclerosis	3.03e-05	0.000889	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	3.02e-05	0.000889	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	3.02e-05	0.000889	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—TNF—multiple sclerosis	3.01e-05	0.000885	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—GPC5—multiple sclerosis	2.83e-05	0.000832	CbGpPWpGaD
Amprenavir—CYP2D6—Biological oxidations—POMC—multiple sclerosis	2.83e-05	0.000831	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.82e-05	0.000829	CbGpPWpGaD
Amprenavir—CYP2C9—Biological oxidations—POMC—multiple sclerosis	2.8e-05	0.000824	CbGpPWpGaD
Amprenavir—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	2.78e-05	0.000816	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—GPC5—multiple sclerosis	2.77e-05	0.000813	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	2.62e-05	0.00077	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	2.62e-05	0.00077	CbGpPWpGaD
Amprenavir—ABCC1—Disease—CD28—multiple sclerosis	2.61e-05	0.000766	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.56e-05	0.000752	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.42e-05	0.000712	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—GPC5—multiple sclerosis	2.4e-05	0.000704	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—RRM1—multiple sclerosis	2.34e-05	0.000689	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	2.34e-05	0.000687	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	2.34e-05	0.000687	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—RRM1—multiple sclerosis	2.29e-05	0.000673	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.29e-05	0.000672	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—CYP27B1—multiple sclerosis	2.28e-05	0.000671	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—CYP24A1—multiple sclerosis	2.28e-05	0.000671	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.21e-05	0.000649	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	2.15e-05	0.000632	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	2.15e-05	0.000632	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—GPC5—multiple sclerosis	2.14e-05	0.000628	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	2.13e-05	0.000626	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	2.13e-05	0.000626	CbGpPWpGaD
Amprenavir—ABCC1—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.1e-05	0.000617	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—BCHE—multiple sclerosis	2.09e-05	0.000614	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—GPC5—multiple sclerosis	2.09e-05	0.000613	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.08e-05	0.000612	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—SRM—multiple sclerosis	2e-05	0.000586	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—RRM1—multiple sclerosis	1.99e-05	0.000583	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.97e-05	0.000578	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—GPC5—multiple sclerosis	1.95e-05	0.000573	CbGpPWpGaD
Amprenavir—ABCC1—Disease—CD86—multiple sclerosis	1.86e-05	0.000546	CbGpPWpGaD
Amprenavir—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.85e-05	0.000543	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—RRM1—multiple sclerosis	1.77e-05	0.000521	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—RRM1—multiple sclerosis	1.73e-05	0.000508	CbGpPWpGaD
Amprenavir—ABCC1—Disease—CCR5—multiple sclerosis	1.65e-05	0.000484	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.63e-05	0.000479	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—RRM1—multiple sclerosis	1.62e-05	0.000475	CbGpPWpGaD
Amprenavir—ABCC1—Disease—HLA-A—multiple sclerosis	1.61e-05	0.000472	CbGpPWpGaD
Amprenavir—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.6e-05	0.000469	CbGpPWpGaD
Amprenavir—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.59e-05	0.000468	CbGpPWpGaD
Amprenavir—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.56e-05	0.000459	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.54e-05	0.000453	CbGpPWpGaD
Amprenavir—ABCC1—Disease—APOE—multiple sclerosis	1.5e-05	0.000441	CbGpPWpGaD
Amprenavir—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.49e-05	0.000437	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.41e-05	0.000413	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.41e-05	0.000413	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.37e-05	0.000404	CbGpPWpGaD
Amprenavir—ABCC1—Disease—CD80—multiple sclerosis	1.36e-05	0.000398	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—BCHE—multiple sclerosis	1.35e-05	0.000396	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.32e-05	0.000389	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—BCHE—multiple sclerosis	1.32e-05	0.000387	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.29e-05	0.000378	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—APOE—multiple sclerosis	1.26e-05	0.000369	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.25e-05	0.000368	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.21e-05	0.000354	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.18e-05	0.000347	CbGpPWpGaD
Amprenavir—ABCC1—Disease—TYK2—multiple sclerosis	1.14e-05	0.000336	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—BCHE—multiple sclerosis	1.14e-05	0.000335	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—POMC—multiple sclerosis	1.08e-05	0.000317	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.08e-05	0.000316	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.08e-05	0.000316	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.07e-05	0.000313	CbGpPWpGaD
Amprenavir—ABCC1—Disease—CD4—multiple sclerosis	1.04e-05	0.000304	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—BCHE—multiple sclerosis	1.02e-05	0.000299	CbGpPWpGaD
Amprenavir—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	9.99e-06	0.000294	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—BCHE—multiple sclerosis	9.93e-06	0.000292	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—ALB—multiple sclerosis	9.84e-06	0.000289	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	9.82e-06	0.000288	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—BCHE—multiple sclerosis	9.36e-06	0.000275	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—BCHE—multiple sclerosis	9.28e-06	0.000273	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—APOE—multiple sclerosis	8.1e-06	0.000238	CbGpPWpGaD
Amprenavir—ABCC1—Disease—STAT3—multiple sclerosis	8.02e-06	0.000236	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—APOE—multiple sclerosis	7.92e-06	0.000233	CbGpPWpGaD
Amprenavir—ABCC1—Disease—MYC—multiple sclerosis	7.45e-06	0.000219	CbGpPWpGaD
Amprenavir—ABCC1—Disease—TGFB1—multiple sclerosis	7.43e-06	0.000218	CbGpPWpGaD
Amprenavir—ABCC1—Disease—MAPK1—multiple sclerosis	7.29e-06	0.000214	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—POMC—multiple sclerosis	6.96e-06	0.000205	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—APOE—multiple sclerosis	6.86e-06	0.000202	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—POMC—multiple sclerosis	6.8e-06	0.0002	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—ALB—multiple sclerosis	6.35e-06	0.000186	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—ALB—multiple sclerosis	6.2e-06	0.000182	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—APOE—multiple sclerosis	6.12e-06	0.00018	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—BCHE—multiple sclerosis	6.12e-06	0.00018	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—APOE—multiple sclerosis	5.98e-06	0.000176	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—POMC—multiple sclerosis	5.89e-06	0.000173	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—APOE—multiple sclerosis	5.63e-06	0.000165	CbGpPWpGaD
Amprenavir—ABCC1—Disease—IL6—multiple sclerosis	5.6e-06	0.000165	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—APOE—multiple sclerosis	5.58e-06	0.000164	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—ALB—multiple sclerosis	5.37e-06	0.000158	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—POMC—multiple sclerosis	5.26e-06	0.000155	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—POMC—multiple sclerosis	5.13e-06	0.000151	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—POMC—multiple sclerosis	4.84e-06	0.000142	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—POMC—multiple sclerosis	4.8e-06	0.000141	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—ALB—multiple sclerosis	4.79e-06	0.000141	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—ALB—multiple sclerosis	4.68e-06	0.000138	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—ALB—multiple sclerosis	4.41e-06	0.00013	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—ALB—multiple sclerosis	4.37e-06	0.000128	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—APOE—multiple sclerosis	3.68e-06	0.000108	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—POMC—multiple sclerosis	3.16e-06	9.29e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—ALB—multiple sclerosis	2.88e-06	8.47e-05	CbGpPWpGaD
